anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Visually impaired and blind adolescents fare poorly in educational attainment compared to adolescents without vision impairment. Rehabilitation holds the potential to compensate for the hindrances that the impairment causes. Many rehabilitation initiatives exist. However, the efficacy of these initiatives remains uncertain. This systematic review assessed which rehabilitation initiatives improve participation in an educational setting for visually impaired and blind adolescents.
METHODS: PubMed, Embase, Scopus, Cinahl, and Cochrane library databases were searched. Only primary studies as randomized controlled trial (parallel group or crossover), cohort studies, case-control studies, qualitative studies, and case-studies were included. Data on the study characteristics, visual impairment, type of intervention, research question, main findings, and implications for practice were extracted from the papers. Critical appraisal was performed using the Critical Appraisal Checklist for Qualitative Research and the Checklist for Quasi-Experimental Studies both from the Joanna Briggs Institute. The data extraction and the critical appraisal were performed independently by two reviewers.
RESULTS: A total of 10 studies with visually impaired and blind adolescents were considered eligible, from an original search result of 3210 studies. In the thematic analysis we identified a heightened focus on different means for studying by making the curriculum content more accessible by applying different audio, tactile, or electronic devices (n = 8). A minor focus in the identified studies (n = 2) was placed on the impact of support from the environment on the development of literacy, for example the support from teachers or parents. Outcome parameters representing more diverse rehabilitation initiatives have not been adequately investigated in the literature. The scientific evidence that we identified was based on few publications with contradictory results and some studies were of questionable quality, limiting the applicability of their findings.
CONCLUSIONS: Overall, the review identified a gap in the evidence regarding rehabilitation initiatives for visually impaired and blind adolescents that enables participation in an educational setting. The overall quality assessment of the 10 studies identified several risks of bias, for which reason the current scientific evidence does not qualify as a basis for decision making, leaving the adolescents in a heightened risk to fall even further behind in the educational system. Further high quality randomized controlled trials are required to establish high-quality evidence.
Arginase 2 (Arg2) is shown herein to control the suppressive activity of regulatory T-Cells (Tregs). Arg2 is deficient in the Tregs of tissues having autoimmune conditions, such as in the skin lesions of psoriasis. Autoimmune conditions may be treated by Arg2 agonists, increasing Treg expression of Arg2, or the administration of Tregs (such as skin-tropic Tregs in the case of epidermal autoimmune conditions) engineered to express Arg2. Further, Treg suppressive activity in cancer blunts the immune response against the tumor and reduces the efficacy of immunotherapy treatment. Cancer may be treated by administration of an Arg2 inhibitor or by administering Tregs (such as tumor-associated Tregs) engineered to have reduced Arg2 expression. Also provided are diagnostic kits and methods, wherein Treg suppressive capacity is assessed by measuring Arg2 activity.
The invention relates to nicergoline sustained-release capsule and the preparation method. The current nicergoline can be taken orally, 2-3 times per day, continuously for at least 6 months, and the doctor will decide further intake or not. The side effect of said medicine mainly comprises low blood pressure, dizzy and stomach pain, and the long term intake increases side effect generation rate. The product in this invention comprises capsule shell and sustained release particle. The comprised materials in sustained release particle and their weight proportion are ad follows:  nicergoline 30-60, retardant 60-120, sustained release film forming material 20-35, packing agent 60, adhesive agent 10, plasticizing agent 2-4, and pore-forming agent 4. The product can replace similar medicine.
A method and system for producing oxygen-rich vapor derived from herb-based plants and extracts from said herb-based plants for consumption by individuals. The method includes transferring a first portion of a base quantity of oxygen-enriched vapor form a volumetric container into a vaporization device. The vaporization device retains an herb-based plant material. The herb-based plant material is used in conjunction with the first portion to produce herb-infused vapor through an atomization process. The herb-infused vapor is then permeated into a mixing chamber with a second portion of the base quantity of oxygen-enriched vapor from the volumetric container. The second portion is then mixed with the herb-infused vapor in order to formulate an oxygen-infused herb vapor. The oxygen-infused herb vapor is then dispensed from the mixing chamber for individual consumption.
Virtual environment with no movement graded at grade 0. Participants complete head and eye exercises within the environment using focus points such as benches and lanterns for a six week treatment program.
Patients with a visible lesion or medium risk cancer will have PSA 6 monthly and MRI scans annually. As per international PIRADS committee guidance the surveillance MRIs will be biparametric MRI scans which last approximately 15 minutes and exclude gadolinium contrast injection. All other patients will undergo PSA 6 monthly and MRI in years 1, 3 and 5. In all patients, a targeted biopsy will be carried out if the MRI PRECISE score is \>/=4.
Gantenerumab, a human monoclonal antibody (mAb), has been thought of as a potential agent to treat Alzheimer's disease (AD) by specifically targeting regions of the amyloid-β (Aβ) peptide sequence. Aβ protein accumulation in the brain leads to amyloid plaques, causing neuroinflammation, oxidative stress, neuronal damage, and neurotransmitter dysfunction, thereby causing cognitive decline in AD. Gantenerumab involves disrupting Aβ aggregation and promoting the breakdown of larger Aβ aggregates into smaller fragments, which facilitates the action of Aβ-degrading enzymes in the brain, thus slowing down the progression of AD. Moreover, Gantenerumab acts as an opsonin, coating Aβ plaques and enhancing their recognition by immune cells, which, combined with its ability to improve the activity of microglia, makes it an intriguing candidate for promoting Aβ plaque clearance. Indeed, the multifaceted effects of Gantenerumab, including Aβ disaggregation, enhanced immune recognition, and improved microglia activity, may position it as a promising therapeutic approach for AD. Of note, reports suggest that Gantenerumab, albeit its capacity to reduce or eliminate Aβ, has not demonstrated effectiveness in reducing cognitive decline. This review, after providing an overview of immunotherapy approaches that target Aβ in AD, explores the efficacy of Gantenerumab in reducing Aβ levels and cognitive decline.
The risk of hypoglycemia is increased when BYETTA is used in combination with a sulfonylurea. Therefore, patients receiving BYETTA and a sulfonylurea may require a lower dose of the sulfonylurea to reduce the risk of hypoglycemia. Patients should be informed that it is also possible that the use of BYETTA with other glucose-independent insulin secretagogues (e.g., meglitinides) could increase the risk of hypoglycemia.

When BYETTA is used in combination with insulin, evaluate the dose of insulin. Consider reducing the dose of insulin in patients at increased risk of hypoglycemia [see Adverse Reactions (6.1)]. Patients treated with BYETTA should be informed that the concurrent use of BYETTA with prandial insulin has not been studied and cannot be recommended.

The symptoms, treatment, and conditions that predispose to development of hypoglycemia should be explained to the patient. The patient's usual instructions for hypoglycemia management should be reviewed and reinforced when initiating BYETTA therapy, particularly when concomitantly administered with a sulfonylurea or insulin [see Warnings and Precautions (5.2)].
BACKGROUND: Infectious diseases are a major cause of mortality in spite of existing public health, anti-microbial and vaccine interventions. We aimed to define plasma proteomic associates of infection mortality and then apply Mendelian randomisation (MR) to yield biomarkers that may be causally associated.
METHODS: We used UK Biobank plasma proteomic data to associate 2923 plasma proteins with infection mortality before 31st December 2019 (240 events in 52,520 participants). Since many plasma proteins also predict non-infection mortality, we focussed on those associated with >1.5-fold risk of infection mortality in an analysis excluding survivors. Protein quantitative trait scores (pQTS) were then used to identify whether genetically predicted protein levels also associated with infection mortality. To conduct Two Sample MR, we performed a genome-wide association study (GWAS) of infection mortality using UK Biobank participants without plasma proteomic data (n = 363,953 including 984 infection deaths).
FINDINGS: After adjusting for clinical risk factors, 1142 plasma proteins were associated with risk of infection mortality (false discovery rate <0.05). 259 proteins were associated with >1.5-fold increased risk of infection versus non-infection mortality. Of these, we identified genetically predicted increasing MERTK concentration was associated with increased risk of infection mortality. MR supported a causal association between increasing plasma MERTK protein and infection mortality (odds ratio 1.46 per unit; 95% CI 1.15- 1.85; p = 0.002).
CONCLUSION: Plasma MERTK is causally associated with infection mortality and warrants exploration as a potential therapeutic target.
NEW MATERIAL:A 4-hydroxyimino-1,2,3,4-tetrahydroquinoline derivative expressed by the formula (R is H, alkyl, halogen substituted lower alkyl, phenyl substituted lower alkyl, phenylalkenyl, aromatic group containing nitrogen or alkyl or phenyl substituted amino). EXAMPLE:6-Chloro-4-hydroxyimino-1-formyl-1,2,3,4-tetrahydroquinoline. USE:An antihydrophic and a diuretic agent with almost no gastric disorder. PROCESS:p-Chloroaniline is heated with an acrylic ester in a solvent, e.g. benzene, or if desired with a base, e.g. sodium hydride, at room temperature or under heating to carry out the Michael addition reaction to obtain a 3-(p-chlorophenylamino) propionic ester. The resultant ester is hydrolyzed and then heated in the presence of  a dehydrating agent to afford the compound expressed by the formula.
Recently a new mode of high flow oxygen therapy has presented on the market where the cannula of high flow have different diameters. Left cannula larger in diameter than the right. These two-nare size high flow nasal cannula are capable of delivering gases at a flow rate of 15-60 L/min, similar to the conventional HFNP but the difference in the diameters provide different levels of positive pressure as compared to conventional HFNP. The two nare nasal cannula will be used for 30 minutes to assess the gas exchange, hemodynamic parameters, the tolerance and comfort of the device to the patient.
In earlier studies, interventions to treat acute kidney injury (AKI) were started after a functional damage of the kidneys was already established. However, none of the interventions had an effect in treating AKI. The Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines recommend implementing different measures in patients at high risk for AKI, but the evidence that the implementation of the bundle (consisting of optimization of hemodynamics and perfusion pressure, avoidance of nephrotoxins and hyperglycemia) can prevent AKI is very weak. Biomarkers can be used to identify patients at high risk for AKI after surgery (prior to the development of AKI). The cell-cycle arrest biomarkers, Tissue Inhibitor of Metalloproteinases-2 (TIMP-2) and Insulin-like growth factor-binding protein 7 (IGFBP7), have been demonstrated to have the best predictive performance for the development of AKI after surgery as compared to other biomarkers. In addition, these biomarkers are not influenced by different co-morbidities or other clinical situations. In the BigpAK1 trial, which was a single-center trial, the authors investigated whether a biomarker-guided implementation of the KDIGO guidelines can reduce the occurrence of AKI in patients undergoing major non-cardiac surgery. The results demonstrate that the implementation of the KDIGO bundle in high risk patients for AKI (\[TIMP-2\]\*\[IGFBP7\] between 0.3 and 2) significantly reduced the occurrence of AKI compared to the standard of care group. However, this was a single center trial which needs to be confirmed in a large trial. Therefore, based on these data, a definitive, prospective, randomized controlled, multicenter study including 1302 surgical patients at high risk for AKI identified by \[TIMP-2\]\*\[IGFBP7\] will be performed.

The goal of this trial is to investigate the effect of the implementation of the KDIGO bundle in patients at high risk for AKI after major surgery compared to standard of care in the same patient population. This biomarker-guided approach (individualized therapy) enables to treat patients at high risk for AKI prior to a functional damage of the kidneys.
The goal of this trial is to evaluate the efficacy of an enhanced Teen Marijuana Check-Up protocol to reach and intervene with non-treatment seeking adolescents who use marijuana heavily. Two hundred fifty adolescents who use marijuana heavily will receive a 2-session individual motivational enhancement therapy. All participants will also be offered the opportunity, over a 12-month period, to repeatedly re-initiate marijuana counseling. Participants will be randomly assigned to receive one of two types of periodic follow-up contacts: Motivational interviewing-based Marijuana Check-Ins (MCI) or Computer Based Control (Comp) sessions.

All participants will be reassessed at the 6, 9, 12, and 15-month anniversaries of enrollment. Following their initial motivational enhancement therapy, the 125 experimental condition participants will additionally have a motivational enhancement treatment "check-in" session with their counselor at the 4, 7, and 10-month anniversaries of enrollment intended to reinforce the maintenance of treatment gains and motivate continued success, increase motivation to change for participants who did not meet their marijuana use goals, and/or prompt utilization of cognitive-behavioral treatment (CBT) sessions as needed. The 125 comparison participants will complete a computer based questionnaire at the same time intervals to serve as an attentional control.
A medical image is obtained and displayed. An electronic image interpretation report of the medical image is generated and displayed. The position of a lesion region in the medical image is input. A link character linked by a hyperlink to the medical image including the input position of the lesion region is inserted into the image interpretation report in such a manner that the link character is distinguishably displayed. The distinguishably displayed link character in the image interpretation report is selected. An index representing the position of the lesion region is displayed in the medical image based on the selection of the link character.
Patients failing to enter or maintain remission by 6 weeks, or with worsening disease at any time after week 2 will be considered failures on an intention to treat basis. Eligible patients at this time at aged 10 or above may receive a 14 day antibiotic course with Doxycycline, amoxicillin and metronidazole.In addition to the description above children who refused to UCD or with low adherence to UCD may be enrolled directly to this arm.
Breathe Well uses the Kaiser Permanente Electronic Health Record (EHR) to identify asthma exacerbation risk factors. For patients with a history of frequent exacerbations or B-agonist overuse, the EHR notifies a nurse who uses an EHR-generated tailored clinical report and patient directed decision support tool to engage and empower patients to develop an action plan in collaboration with providers. EHR-templated notes and order sets facilitate care plan execution. Poor controller medication adherence or unaddressed smoking results in the patient being automatically enrolled in an IBCT medication refill or smoking cessation program. Breathe Well uses multiple EHR functions and a patient and provider team to address barriers to evidence-based asthma care for providers.The study will be conducted in 26 primary care clinics of Kaiser Permanente Colorado (KPCO) using a pragmatic clinical trial design. Up to 15,000 high-risk asthma patients will be assigned to Breathe Well or guideline-based usual care based on their clinic.
Depending on the severity and duration of symptoms, total daily dosage for  adult psychotic patients may range initially from 2.5 to 10 mg and should be divided and given at six- to eight- hour intervals. 

The smallest amount that will produce the desired results must be carefully determined for each individual, since optimal dosage levels of this potent drug may vary from patient to patient. In general, the oral dose has been found to be approximately two to three times the parenteral dose of fluphenazine. Treatment is best instituted with a low initial dosage, which may be increased, if necessary, until the desired clinical effects are achieved. Therapeutic effect is often achieved with doses under 20 mg daily. Patients remaining severely disturbed or inadequately controlled may require upward titration of dosage. Daily doses up to 40 mg may be necessary; controlled clinical studies have not been performed to demonstrate safety of prolonged administration of such doses.

When symptoms are controlled, dosage can generally be reduced gradually to daily maintenance doses of 1 to 5 mg, often given as a single daily dose. Continued treatment is needed to achieve maximum therapeutic benefits; further adjustments in dosage may be necessary during the course of therapy to meet the patient's requirements.

For psychotic patients who have been stabilized on a fixed daily dosage of orally administered Fluphenazine Hydrochloride dosage forms, conversion to the long-acting injectable Fluphenazine Decanoate may be indicated [see package insert for Fluphenazine Decanoate Injection for conversion information].

For geriatric patients, the suggested starting dose is 1 to 2.5 mg daily, adjusted according to the response of the patient. 

When the Oral Concentrate dosage form is to be used, the desired dose (measured by a calibrated device only) should be added to at least 60 mL (2 fl oz) of a suitable diluent just prior to administration to ensure palatability and stability. Suggested diluents include tomato or fruit juice, milk, and uncaffeinated soft drinks. The Oral Concentrate should not be mixed with beverages containing caffeine (coffee, cola), tannics (tea), or pectinates (apple juice) because of the potential incompatibility. 

Fluphenazine Hydrochloride Injection USP is useful when psychotic patients are unable or unwilling to take oral therapy.
PURPOSE: A composition for preventing or treating diabetes, which contains marine microorganism metabolite is provided to ensure the effect of suppressing beta cell death with low price. CONSTITUTION: A composition for preventing or treating diabetes contains marine microorganism metabolite as an active ingredient. The marine microorganism is Halomonas sp. The microorganism is Halomonas CCRB608(KCTC 11313BP). The marine microorganism metabolite is extracted using methanol and hexane solvent. A method for producing the composition comprises: a step of culturing marine microorganism strain; a step of extracting cultured strain using solvent; a step of concentrating the extracted marine microorganism metabolite; and a step of isolating concentrated metabolite.
The following adverse reactions associated with the use of parenteral phytonadione were identified in clinical studies or post-marketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Severe hypersensitivity reactions, including anaphylactoid reactions and deaths, have been reported following parenteral administration. The majority of these reported events occurred following intravenous administration.

Transient “flushing sensations” and “peculiar” sensations of taste have been observed with parenteral phytonadione, as well as instances of dizziness, rapid and weak pulse, profuse sweating, brief hypotension, dyspnea, and cyanosis.

Hyperbilirubinemia has been observed in the newborn following administration of parenteral phytonadione. This has occurred primarily with doses above those recommended.

To report SUSPECTED ADVERSE REACTIONS, contact AvKARE at 1-855-361-3993 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Specific remedies against diseases occasioned by foreign bodies such as poisons (including alkaloids), foreign albumens, toxins, and bacteria, are prepared by causing digestive ferments such as pepsin, pancreatin, and trypsin to act in excess on the particular foreign bodies.  It is stated that a combination comprising the ferment and a protective layer of the foreign body, or its products of decomposition, is obtained so that the ferment is not subsequently inactivated by larger quantities of the foreign body. Non-fermentative substances obtained from the gall, brain, renal glands, thymus gland, thyroid gland, &c. may also be added.  The reaction may be carried out by injecting both the ferment or ferments and a foreign body such as diphtheria toxin into an animal and then recovering the antitoxic serum in the usual way, or may be carried out in vitro, a substrate consisting of the inactivated blood serum of the same species of animal as that yielding the ferment being employed in some cases.  In an example carcinoma cells suspended in inactivated blood serum are treated first with an acid solution of pepsin, then neutralized and treated with pancreatin and sodium cholicum (obtained from bovine gall), and the resultant product evaporated to dryness at low temperature or precipitated with alcohol.  A disinfectant which does not act on the ferment, such as formaldehyde or hexamethylenetetramine, may be added as a stabilizer. In other examples tuberculosis bacteria are treated in acid solution with pepsin and a phosphatide and then in alkaline solution with pancreatin and sodium cholicum; diphtheria toxin is treated with pancreatin; and digitalis leaves are treated with pepsin and then with pancreatin.  Keratin may also be treated.  The remedies may be administered by injection or by the mouth.  Specifications 12523/09, [Class 81 (i), Disinfecting &c.], and 5957/13 are referred to.